Literature DB >> 7381634

Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

P H Beaudry, M I Marks, D McDougall, K Desmond, R Rangel.   

Abstract

A controlled study was designed to clarify the indications for antibiotic therapy in children with advanced cystic fibrosis hospitalized with respiratory exacerbations. Twenty-two children with severe CF and signs of acute lower respiratory infection were randomly assigned to receive either cloxacillin or carbenicillin plus gentamicin administered intravenously for ten days. Other aspects of therapy were constant. The groups were comparable in all respects and Pseudomonas aeruginosa was the predominant sputum pathogen in most patients. Clinical improvement, chest radiograph changes, evidence of airway obstruction, and bacteriologic flora of sputum were no different regardless of the regimen used. These results suggest that the use of anti-Pseudomonas medication in these children may not always be necessary. These observations need to be confirmed by blind-controlled studies in larger numbers of patients with mild as well as severe respiratory involvement.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7381634     DOI: 10.1016/s0022-3476(80)80155-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  26 in total

Review 1.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

2.  Conformity of bacterial growth in sputum and contamination free endobronchial samples in patients with cystic fibrosis.

Authors:  H Gilljam; A S Malmborg; B Strandvik
Journal:  Thorax       Date:  1986-08       Impact factor: 9.139

Review 3.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Amanda Plummer; Martin Wildman; Tim Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

4.  Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. British Thoracic Society Research Committee.

Authors: 
Journal:  Thorax       Date:  1985-05       Impact factor: 9.139

5.  Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis.

Authors:  G Steinkamp; B Tümmler; R Malottke; H von der Hardt
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

6.  Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion.

Authors:  E Autret; S Marchand; M Breteau; B Grenier
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Changes in nocturnal oximetry after treatment of exacerbations in cystic fibrosis.

Authors:  M B Allen; A F Mellon; E J Simmonds; R L Page; J M Littlewood
Journal:  Arch Dis Child       Date:  1993-08       Impact factor: 3.791

Review 8.  The impact of respiratory viral infections in patients with cystic fibrosis.

Authors:  C G Prober
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 9.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

10.  Endotoxaemia in cystic fibrosis: response to antibiotics.

Authors:  G Taylor; C Stern; M Silverman; M Mearns
Journal:  Arch Dis Child       Date:  1983-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.